CAMBRIDGE, Engeland – (BUSINESS WIRE) – Cycle Pharmaceuticals, een particulier, wereldwijd, patiëntgericht biotechnologiebedrijf dat zich richt op het ontwikkelen en leveren van medicijnen voor zeldzame ziekten, is genoemd als een van de Sunday Times 10 Tech Track Ones to Watch 2020 .

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20200907005368/en/

The Sunday Times lanceerde 20 jaar geleden de Tech Track 100-lijst om de snelst groeiende particuliere technologiebedrijven van Groot-Brittannië te erkennen. De Tech Track 10 Ones to Watch toont bedrijven die nog niet voldoen aan de criteria van de belangrijkste Tech Track 100-ranglijst, maar die een sterke omzetgroei hebben gerealiseerd, een sterke omzetgroei voorspellen en over innovatieve technologieën beschikken.

Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020

CAMBRIDGE, England–(BUSINESS WIRE)– Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has been featured as one of the Sunday Times 10 Tech Track Ones to Watch 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200907005368/en/

The Sunday Times launched the Tech Track 100 list 20 years ago to recognise Britain’s fastest-growing private technology companies. The Tech Track 10 Ones to Watch showcases companies that do not yet meet the criteria of the main Tech Track 100 league table, but which have achieved strong sales growth, are forecasting strong sales growth, and have innovative technologies.

The Sunday Times Tech Track 100 supplement including the 10 Ones to Watch was published on Sunday 6^th September 2020, within the business section of the Sunday Times. The digital edition can be downloaded from: www.fasttrack.co.uk.

Earlier this week, Cycle announced a $25m debt financing from Deutsche Bank AG.

About Cycle Pharmaceuticals

Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community. We focus on rare metabolic and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200907005368/en/

Contacts

Cycle Pharmaceuticals

Paula Bekinschtein

Head of Global Marketing

Email: marketing@cyclepharma.com
Tel.: +44-1223-354118